I'll be carefully reading the quarterly given the failure of...

I'll be carefully reading the quarterly given the failure of their initial trial of the new "Oraline" during this last quarter.

Hopefully they will be more upbeat about other acquisitions / transactions rather than emphasizing Oraline progress/failure.

If there is an indication that they are continuing to focus on Oraline rather than other ideas I am gonna reconsider whether to hold this stock. IMO Oraline was worth a shot given the low costs involved, but probably not now after failing the first product run.

C'mon management give us something to chew on!
Don't want to just hear "....progress with Oraline...." and "....continuing to assess opportunities...."!